These interesting findings could encourage the evaluation of an association of proton therapy with for example an anti-CTLA4 or an anti-CCR4, which, by targeting Tregs, induce reactivation of CD8+ T cells against tumor cells46. Here, CCR4 is linked to neoplasm.